E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
Chronic fatigue syndrome.
Devanur, L D, Kerr, J R · Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2006 · DOI
Quick Summary
ME/CFS affects about 1 in 100 to 1 in 250 people worldwide and is diagnosed based on clinical symptoms after ruling out other diseases. Research shows that ME/CFS likely involves multiple factors: immune system problems, stress, infections (such as Epstein-Barr virus), and exposure to certain chemicals or toxins. Currently there is no proven cure, but treating underlying infections may help some patients.
Why It Matters
This review consolidates evidence that ME/CFS is a multifactorial disease with biological substrates—immune, endocrine, and infectious—rather than purely psychiatric, validating patient experiences and directing research toward biomarker development and mechanism-based treatments. Understanding the interplay between stress, infection, and immune dysfunction provides a framework for identifying therapeutic targets.
Observed Findings
- Immune system abnormalities and chronic immune activation documented in ME/CFS patients
- Dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis identified in studies
- Multiple microbial infections associated with ME/CFS (EBV, enterovirus, parvovirus B19, Coxiella burnetii, Chlamydia pneumoniae)
- Emotional stress shown to impair immune clearance of infections and determine symptom development upon viral infection
- Estimated worldwide prevalence of 0.4–1% with approximately 240,000 patients in the UK
Inferred Conclusions
- ME/CFS pathogenesis involves both host factors (immune dysregulation, HPA axis dysfunction, emotional stress) and environmental factors (infections, vaccinations, chemical exposures)
- Emotional stress plays a pivotal mechanistic role by reducing immune competence and triggering HPA activation
- Current clinical management is limited; urgent priorities include molecular characterization of disease mechanisms, development of protein biomarkers for diagnosis, and targeted antimicrobial treatments
- The diagnostic distinction between ME/CFS and depression is clinically and biologically meaningful
Remaining Questions
- What are the specific molecular mechanisms by which identified pathogens and toxins initiate or perpetuate immune activation in genetically or functionally susceptible individuals?
What This Study Does Not Prove
This review does not establish causality for any specific pathogen or toxin; it documents associations and temporal relationships. It does not provide prevalence estimates based on prospective cohort data or demonstrate that identified abnormalities are disease-specific rather than secondary consequences of chronic illness. The distinction between emotional stress and depression is asserted but not formally tested in this abstract.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:CytokinesBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:PEM Not Defined
Metadata
- DOI
- 10.1016/j.jcv.2006.08.013
- PMID
- 16978917
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →